Specific targeted antiviral therapy for hepatitis C

Research output: Contribution to journalReview article

Abstract

Since the discovery of the hepatitis C virus (HCV) as the major cause of non-A, non-B hepatitis in 1989, the search for specific targeted antiviral therapy for HCV (STAT-C) has been underway. Recently, major advances in the understanding of HCV biology and the development of an in vitro system of HCV replication have contributed to the selection of multiple candidate drugs for the treatment of hepatitis C. In 2006, five such candidate drugs have entered phase 11 clinical trials in patients chronically infected with hepatitis C, including small molecule inhibitors of the HCV NS3 serine protease and NS5B RNA-dependent RNA polymerase. This review focuses on hepatitis C protease and polymerase inhibitors that have progressed to phase 11 clinical development, foreshadowing the era of STAT-Cs.

Original languageEnglish (US)
Pages (from-to)5-13
Number of pages9
JournalCurrent gastroenterology reports
Volume9
Issue number1
DOIs
StatePublished - Mar 1 2007

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Specific targeted antiviral therapy for hepatitis C'. Together they form a unique fingerprint.

  • Cite this